Site search
2811 results for '' found
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies (NCT04778410)
A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients with Myeloid Malignancies (NCT04778410)
/
A Phase 2 Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults (NCT05729568)
A Phase 2 Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults (NCT05729568)
/
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (NCT05
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (NCT05
/
[NHL37] An open-label, single-arm, phase 2 trial of GlOfitamab anD pIrtobrutinib [LOXo-305] in patients with mantle cell lymphoma and prior exposure to a BTK inhibitor – GOlDiLOX (NCT05833763)
[NHL37] An open-label, single-arm, phase 2 trial of GlOfitamab anD pIrtobrutinib [LOXo-305] in patients with mantle cell lymphoma and prior exposure to a BTK inhibitor – GOlDiLOX (NCT05833763)
/
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precurs
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precurs
/
A PHASE Ib, OPEN-LABEL, MULTICENTER DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF XmAb24306 IN COMBINATION WITH CEVOSTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY M
A PHASE Ib, OPEN-LABEL, MULTICENTER DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF XmAb24306 IN COMBINATION WITH CEVOSTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY M
/
AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE COMBINATION OF CEVOSTAMAB AND ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE
AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE COMBINATION OF CEVOSTAMAB AND ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE
/
A Phase 1b, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple M
A Phase 1b, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple M
/
AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF CEVOSTAMAB AS MONOTHERAPY AND CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE OR CEVOSTAMAB PLU
AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF CEVOSTAMAB AS MONOTHERAPY AND CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE OR CEVOSTAMAB PLU
/
A PHASE Ia/Ib DOSE-ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN P
A PHASE Ia/Ib DOSE-ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN P
/